Specificity of Intestinal Immunoglobulin A

肠道免疫球蛋白 A 的特异性

基本信息

  • 批准号:
    9296031
  • 负责人:
  • 金额:
    $ 48.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-15 至 2021-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT More than 80% of mammalian antibody-secreting cells reside in the intestinal mucosa and secrete antibodies of the immunoglobulin A (IgA) isotype. IgA deficiency is common in humans and predisposes toward various intestinal pathologies including inflammatory bowel disease, celiac disease, and allergy. However, despite decades of research, the specificity of IgA remains elusive. IgA coats a fraction of the intestinal microbiota, yet the identities of the bacteria targeted by IgA and the types of humoral responses involved remain unknown. IgA may also target dietary antigens, but it is unclear whether most IgA is directed against dietary antigens, commensal microbiota, or other intestinal antigens. Lastly, specific antigens recognized by homeostatic IgA antibodies have not been described. Here we present extensive preliminary data characterizing the commensal bacteria targeted by IgA using a novel method involving bacterial flow cytometry and 16S rRNA gene sequencing, termed IgA-Seq. We further present a method for cloning and expression of recombinant monoclonal antibodies from single intestinal IgA-producing cells and rapid characterization of their reactivity against microbiota using IgA-Seq. Finally, we detail a plan for determining the antigenic targets of these antibodies with the following specific aims: 1) To characterize the origin and frequency of commensal-specific B cells; and 2) To determine the specificities of single IgA antibodies. These data will be integrated to develop a working understanding of the commensal bacteria and specific bacterial and/or dietary antigens that drive homeostatic IgA responses. An understanding of the specificity of IgA will clarify hypotheses regarding its elusive function. Further, manipulation of the IgA response may represent a promising therapeutic approach to various microbiota-associated pathologies including inflammatory bowel disease, celiac disease, obesity, and diabetes, but cannot be achieved without a thorough understanding of its specificity. Lastly, our studies will generate a large panel of monoclonal antibodies specific for commensal microbiota that may allow manipulation and characterization of defined bacterial subsets in healthy or dysbiotic microbiota and may have applications as research, diagnostic, or therapeutic tools.
摘要 超过80%的哺乳动物抗体分泌细胞驻留在肠粘膜中并分泌抗体 免疫球蛋白A(IgA)同种型。IgA缺乏症在人类中很常见,并且容易导致各种疾病。 肠道病变,包括炎性肠病、乳糜泻和过敏。但尽管 几十年的研究,IgA的特异性仍然难以捉摸。IgA覆盖了一小部分肠道微生物群, IgA靶向的细菌的身份和所涉及的体液应答的类型仍然未知。 IgA也可以靶向饮食抗原,但目前还不清楚大多数IgA是否针对饮食抗原, 肠道微生物或其他肠道抗原。最后,由稳态IgA识别的特异性抗原 抗体尚未描述。在这里,我们提出了广泛的初步数据, 使用涉及细菌流式细胞术和16S rRNA的新方法通过IgA靶向肠道细菌 基因测序,称为IgA-Seq。我们进一步提出了一种克隆和表达重组 来自单个肠IgA产生细胞的单克隆抗体及其反应性的快速表征 针对微生物群使用IgA-Seq.最后,我们详细介绍了一个计划,以确定这些抗原的目标, 具有以下特定目的的抗体:1)表征肿瘤特异性抗体的起源和频率, B细胞; 2)确定单一IgA抗体的特异性。这些数据将被整合, 对肠道细菌和特定的细菌和/或饮食抗原的工作理解, 稳态IgA反应。对IgA特异性的理解将澄清关于其 难以捉摸的功能。此外,操纵IgA反应可能代表了一种有前途的治疗方法, 各种微生物群相关的病理,包括炎性肠病、乳糜泻、肥胖症, 糖尿病,但不能实现没有彻底了解其特异性。最后,我们的研究将 产生大量对共生微生物群特异性的单克隆抗体,这可能允许 操纵和表征健康或生态失调微生物群中定义的细菌亚群,并且可能具有 作为研究、诊断或治疗工具的应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALBERT S. BENDELAC其他文献

ALBERT S. BENDELAC的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALBERT S. BENDELAC', 18)}}的其他基金

Transcriptional Regulation of Innate-Like T Cells
先天样 T 细胞的转录调控
  • 批准号:
    10441712
  • 财政年份:
    2022
  • 资助金额:
    $ 48.94万
  • 项目类别:
Development of Intestinal Polyreactive IgA B Cells
肠道多反应性 IgA B 细胞的发育
  • 批准号:
    10543053
  • 财政年份:
    2019
  • 资助金额:
    $ 48.94万
  • 项目类别:
Development of Intestinal Polyreactive IgA B Cells
肠道多反应性 IgA B 细胞的发育
  • 批准号:
    10321246
  • 财政年份:
    2019
  • 资助金额:
    $ 48.94万
  • 项目类别:
Development of Intestinal Polyreactive IgA B Cells
肠道多反应性 IgA B 细胞的发育
  • 批准号:
    10078246
  • 财政年份:
    2019
  • 资助金额:
    $ 48.94万
  • 项目类别:
A common hematopoietic precursor to innate lymphoid cells
先天淋巴细胞的常见造血前体
  • 批准号:
    9312731
  • 财政年份:
    2014
  • 资助金额:
    $ 48.94万
  • 项目类别:
A common hematopoietic precursor to innate lymphoid cells
先天淋巴细胞的常见造血前体
  • 批准号:
    9110098
  • 财政年份:
    2014
  • 资助金额:
    $ 48.94万
  • 项目类别:
A common hematopoietic precursor to innate lymphoid cells
先天淋巴细胞的常见造血前体
  • 批准号:
    8612741
  • 财政年份:
    2014
  • 资助金额:
    $ 48.94万
  • 项目类别:
Allergic inflammation in genetic models of lung ILC2 deficiency
肺 ILC2 缺陷遗传模型中的过敏性炎症
  • 批准号:
    8576628
  • 财政年份:
    2013
  • 资助金额:
    $ 48.94万
  • 项目类别:
Allergic inflammation in genetic models of lung ILC2 deficiency
肺 ILC2 缺陷遗传模型中的过敏性炎症
  • 批准号:
    8847790
  • 财政年份:
    2013
  • 资助金额:
    $ 48.94万
  • 项目类别:
Control of lymphoid effector programs by the E3 ligase cullin 3
E3 连接酶 cullin 3 控制淋巴效应程序
  • 批准号:
    8651505
  • 财政年份:
    2013
  • 资助金额:
    $ 48.94万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 48.94万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 48.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了